With a Brexit deal still out of sight, there have been intensified warnings in the UK about potential disruptions to medicine supplies that could follow a no-deal scenario.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has convened an Expert Working Group (EWG) to assess the risks and benefits of opioid medicines and see if current UK reg
Despite the government insisting that Brexit will have no negative fallout, the UK's drugs regulator is consulting on whether it can become a standalone body with no links to European count
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.